Post-Market Surveillance Report
Summary
The Post-Market Surveillance Report documents your systematic analysis of device safety and performance data collected during a defined surveillance period. This report synthesizes vigilance data, complaints, incidents, and trend analyses to demonstrate ongoing device safety and identify any emerging risks requiring action.
Why is Post-Market Surveillance Report important?
The Post-Market Surveillance Report serves as your regulatory evidence that you’re actively monitoring device safety and responding appropriately to emerging risks. Regulatory authorities use these reports to assess your post-market oversight capabilities and ensure your device continues to meet safety and performance requirements after market authorization. Without comprehensive surveillance reporting, you risk regulatory enforcement actions, loss of market authorization, and potential liability for unaddressed safety issues.
Regulatory Context
Under 21 CFR Part 820 (Quality System Regulation) and various FDA guidance documents:
- Post-market surveillance studies under 21 CFR 822 require periodic reporting
- MDR reporting (21 CFR 803) incidents must be included in surveillance analysis
- 522 Post-Market Surveillance Studies require periodic reporting to FDA
- Must demonstrate systematic data collection and trend analysis
Special attention required for:
- Devices under FDA enforcement actions requiring enhanced surveillance
- Class III devices with intensive surveillance requirements
- Software updates that may affect safety profiles
- Combination products requiring coordinated surveillance approaches
Under 21 CFR Part 820 (Quality System Regulation) and various FDA guidance documents:
- Post-market surveillance studies under 21 CFR 822 require periodic reporting
- MDR reporting (21 CFR 803) incidents must be included in surveillance analysis
- 522 Post-Market Surveillance Studies require periodic reporting to FDA
- Must demonstrate systematic data collection and trend analysis
Special attention required for:
- Devices under FDA enforcement actions requiring enhanced surveillance
- Class III devices with intensive surveillance requirements
- Software updates that may affect safety profiles
- Combination products requiring coordinated surveillance approaches
Under EU MDR 2017/745:
- Post-Market Surveillance Report required under Article 84
- Must comply with Annex III requirements for surveillance documentation
- Periodic Safety Update Reports (PSURs) may incorporate surveillance findings
- Notified body may request surveillance reports for assessment
Special attention required for:
- High-risk devices requiring enhanced surveillance frequency
- Clinical evaluation updates based on surveillance findings
- EUDAMED integration for incident tracking
- Trend reporting with statistical significance assessment
Guide
Your Post-Market Surveillance Report must provide comprehensive analysis of all surveillance data collected during the reporting period, demonstrating systematic monitoring and appropriate response to safety signals.
Data Collection and Sources
Gather vigilance data from multiple international databases including FDA MAUDE, FDA Recalls, BfArM, and Swissmedic. Use consistent search keywords related to your device, technology class, and medical conditions. Document your search methodology and results comprehensively.
Compile complaints data from your complaint management system, focusing on safety-related complaints, performance issues, and user feedback. Calculate complaint rates using the formula: Complaint Rate = Complaints / Sales Volume. Track both serious incidents and non-serious events.
Analyze corrective and preventive actions (CAPAs) implemented during the surveillance period. Document CAPA effectiveness, timeline compliance, and recurring issues that may indicate systematic problems requiring additional intervention.
Statistical Trend Analysis
Perform trend analysis using appropriate statistical methods such as the Mann-Kendall test for non-parametric data, regression analysis for linear trends, or Nelson Rules for control charts. Assess frequency patterns, severity trends, and seasonal variations over the surveillance period.
Evaluate new risks identified through surveillance activities and determine whether they require risk management file updates. Assess whether existing risk controls remain adequate or require enhancement based on real-world performance data.
Update benefit-risk analysis by incorporating surveillance findings into your overall device benefit-risk assessment. Consider whether new data affects your clinical evaluation conclusions or requires labeling updates.
Reporting and Documentation Requirements
Structure your report systematically covering scope, data inputs, trend analysis, and conclusions. Ensure traceability between surveillance plan objectives and report findings.
Document limitations of your surveillance activities including data gaps, methodological constraints, and areas requiring enhanced monitoring. This demonstrates transparency and continuous improvement commitment.
Prepare regulatory submissions based on surveillance findings, including incident reports, labeling updates, or design change notifications as required by your findings.
Example
Scenario: You manufacture a wearable cardiac monitoring device and prepare your annual Post-Market Surveillance Report covering 12 months of surveillance data including vigilance searches, complaint analysis, and trend assessment.
Post-Market Surveillance Report for CardioWatch Pro Wearable Monitor
1. Scope and Overview This report covers post-market surveillance activities for CardioWatch Pro v4.2 from January 1, 2024 to December 31, 2024. Analysis of 2,847 complaints, vigilance database searches, and trend analysis identified no significant safety signals requiring immediate regulatory action.
2. Surveillance Data Analysis
| Data Source | Records Analyzed | Safety-Related | Action Required |
|---|---|---|---|
| Customer Complaints | 2,847 | 23 | 3 CAPAs initiated |
| FDA MAUDE | 156 similar devices | 12 relevant | Monitor for trends |
| Internal Incidents | 8 | 2 | Updated user manual |
3. Trend Analysis Results Mann-Kendall test (p = 0.23) showed no statistically significant trend in complaint rates over the surveillance period. Seasonal variation observed with higher complaint rates in Q2 correlating with increased physical activity.
4. Risk Management Updates Two new risks identified: battery performance degradation during extreme temperatures and skin irritation from extended wear. Both risks added to risk management file with appropriate control measures.
5. Conclusions Surveillance data confirms acceptable safety profile with no emerging risks requiring immediate action. Continued monitoring recommended for exercise-related performance issues. Next surveillance report due December 31, 2025.